Answers are grounded in this paper and cite their sources.
A quality management program was designed to eliminate false positive serological testing after administration of intravenous gamma globulin (IVIgG). The intervention and follow‐up chart review was performed in a tertiary care teaching hospital. After the index false positive test was reported, a multidisciplinary team sent memos to all affiliated physicians and devised a warning label to use in the patient charts after IVIgG administration. After the intervention, follow‐up of 28 patients who received a total of 162 doses of IVIgG revealed that five had at least one serologic test ordered which might have produced a false positive. However, chart review suggested that these serologic results did not influence patient treatment. Serological testing after IVIgG administration can generate erroneous results that can lead to costly delays in diagnosis and treatment. Process control actions can proactively foster proper laboratory ordering practices and interpretation.
No takes yet. Share an insight, caveat, or question.
Stricker et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: